Kyaresta

Anastrozole, the active ingredient in Kyaresta, is an aromatase inhibitor presented as an oral tablet for oral use. It reduces estrogen production and is indicated for the treatment of estrogen receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Kyaresta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our global network ensures reliable sourcing, regulatory adherence, and timely delivery to meet the needs of oncology treatment programs across multiple regions and supports clinical trial supply chains.

Kyaresta (anastrozole) is used in hormone‑dependent breast cancer management, targeting estrogen synthesis pathways. - Adjuvant treatment of estrogen receptor‑positive breast cancer: helps lower the risk of disease recurrence after primary surgery and radiation in postmenopausal women. - Metastatic breast cancer therapy: provides disease control by decreasing estrogen‑driven tumor growth, improving progression‑free survival in advanced, hormone‑responsive cases. - Neoadjuvant therapy for ER‑positive tumors: may reduce tumor size and improve surgical outcomes when given before definitive surgery in postmenopausal patients. - Extended adjuvant therapy after tamoxifen: continues estrogen suppression to further reduce recurrence risk following 5 years of tamoxifen treatment.

Anastrozole may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Hot flashes: transient episodes of increased skin temperature and sweating, often occurring at night. - Joint pain: arthralgia affecting knees, hips or hands, which may limit mobility. - Nausea: mild stomach upset, often transient, may be alleviated with food. - Fatigue: general tiredness without exertion, can affect daily activities. - Headache: mild to moderate intensity, may respond to simple analgesics. - Mood changes: irritability or depression, should be reported if persistent. Serious or Rare Side Effects: - Severe bone loss: increased risk of osteoporosis and fractures, especially with long‑term use. - Cardiovascular events: rare cases of thromboembolic disease, such as deep vein thrombosis. - Liver dysfunction: elevated transaminases indicating hepatic injury, may require monitoring. - Allergic reactions: rash, pruritus, or anaphylaxis, requiring immediate medical attention.

Before prescribing Kyaresta, clinicians should consider several precautionary measures to ensure patient safety. - Assess bone health: evaluate baseline bone mineral density and consider calcium/vitamin D supplementation. - Monitor liver function: perform periodic liver enzyme tests during therapy. - Review cardiovascular risk: consider history of thromboembolic events before initiating treatment. - Avoid use in pregnancy: drug is contraindicated; ensure effective contraception in women of childbearing potential. - Discontinue before surgery: stop Kyaresta at least 2 weeks prior to elective procedures to reduce wound healing complications. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Kyaresta can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Concurrent use with estrogen replacement therapy: negates aromatase inhibition and reduces therapeutic benefit. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly decrease anastrozole plasma levels. - Anticoagulants (warfarin): may increase bleeding risk; monitor INR closely. Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may exacerbate hot flashes. - Tamoxifen: combined use is not recommended due to opposing mechanisms; consider sequential therapy. - Cholesterol‑lowering agents (statins): may modestly increase anastrozole concentrations; observe for side effects.